Precision Wealth Strategies LLC Invests $412,000 in ADMA Biologics, Inc. (NASDAQ:ADMA)

Precision Wealth Strategies LLC acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,617 shares of the biotechnology company’s stock, valued at approximately $412,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. increased its holdings in ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after buying an additional 1,442,799 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in ADMA Biologics by 1.1% in the second quarter. Assenagon Asset Management S.A. now owns 3,382,174 shares of the biotechnology company’s stock valued at $37,813,000 after buying an additional 35,707 shares in the last quarter. Driehaus Capital Management LLC increased its holdings in ADMA Biologics by 17.3% in the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock valued at $33,860,000 after buying an additional 447,743 shares in the last quarter. Mesirow Institutional Investment Management Inc. purchased a new position in ADMA Biologics in the first quarter valued at about $17,221,000. Finally, Renaissance Technologies LLC increased its holdings in ADMA Biologics by 28.7% in the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock valued at $28,868,000 after buying an additional 575,100 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on ADMA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of ADMA Biologics in a report on Monday, October 14th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.50.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other ADMA Biologics news, Director Jerrold B. Grossman sold 136,861 shares of ADMA Biologics stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total value of $2,363,589.47. Following the completion of the sale, the director now directly owns 467,305 shares of the company’s stock, valued at approximately $8,070,357.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock valued at $8,224,121 in the last ninety days. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Trading Down 1.0 %

Shares of ADMA opened at $15.62 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. The firm has a 50 day simple moving average of $18.07 and a 200-day simple moving average of $12.80. ADMA Biologics, Inc. has a 1-year low of $3.06 and a 1-year high of $21.13. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of -781.00 and a beta of 0.62.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. During the same period last year, the company posted ($0.02) EPS. The company’s revenue was up 78.4% on a year-over-year basis. Equities analysts forecast that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.